Skip to main content

Peer Review reports

From: The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma

Original Submission
9 Jan 2021 Submitted Original manuscript
11 Jun 2021 Author responded Author comments - Oliver Coen
Resubmission - Version 2
11 Jun 2021 Submitted Manuscript version 2
14 Jun 2021 Editorially accepted
1 Jul 2021 Article published 10.1186/s12885-021-08509-w

You can find further information about peer review here.

Back to article page